keyword
MENU ▼
Read by QxMD icon Read
search

ADCC humans

keyword
https://www.readbyqxmd.com/read/29748553/anticancer-activity-and-antibody-dependent-cell-mediated-cytotoxicity-of-novel-anti-nucleolin-antibodies
#1
Sofia Romano, Vera Moura, Sérgio Simões, João Nuno Moreira, João Gonçalves
Nucleolin arises as a relevant target for cancer therapy, as it is overexpressed at the surface of cancer and angiogenic endothelial cells thus enabling a dual cellular targeting strategy. Immunotherapeutic strategies, albeit of proven therapeutic relevance, have been scarcely explored against this target. Therefore, this work aimed at engineering an anti-nucleolin VHH-based antibody capable of triggering anticancer immune responses. Herein, anti-nucleolin VHHs have been generated upon grafting F3 peptide-derived nucleolin-binding sequences onto a VHH CDR1 or CDR3...
May 10, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29748373/slan-monocytes-and-macrophages-mediate-cd20-dependent-b-cell-lymphoma-elimination-via-adcc-and-adcp
#2
William Vermi, Alessandra Micheletti, Giulia Finotti, Cristina Tecchio, Federica Calzetti, Sara Costa, Mattia Bugatti, Stefano Calza, Claudio Agostinelli, Stefano Pileri, Piera Balzarini, Alessandra Tucci, Giuseppe Rossi, Lara Furlani, Giuseppe Todeschini, Alberto Zamò, Fabio Facchetti, Luisa Lorenzi, Silvia Lonardi, Marco A Cassatella
Terminal tissue differentiation and function of slan+ monocytes in cancer is largely unexplored. Our recent studies demonstrated that slan+ monocytes differentiate into a distinct subset of dendritic cells (DC) in human tonsils and that slan+ cells colonize metastatic carcinoma-draining lymph nodes. Herein, we report by retrospective analysis of multi-institutional cohorts that slan+ cells infiltrate various types of non-Hodgkin lymphomas (NHL), particularly the diffuse large B-cell lymphoma (DLBCL) group, including the most aggressive, nodal and extra-nodal, forms...
May 10, 2018: Cancer Research
https://www.readbyqxmd.com/read/29740451/therapeutic-administration-of-broadly-neutralizing-fi6-antibody-reveals-lack-of-interaction-between-human-igg1-and-pig-fc-receptors
#3
Sophie B Morgan, Barbara Holzer, Johanneke D Hemmink, Francisco J Salguero, John C Schwartz, Gloria Agatic, Elisabetta Cameroni, Barbara Guarino, Emily Porter, Pramila Rijal, Alain Townsend, Bryan Charleston, Davide Corti, Elma Tchilian
Influenza virus infection is a significant global health threat. Because of the lack of cross-protective universal vaccines, short time window during which antivirals are effective and drug resistance, new therapeutic anti-influenza strategies are required. Broadly, cross-protective antibodies that target conserved sites in the hemagglutinin (HA) stem region have been proposed as therapeutic agents. FI6 is the first proven such monoclonal antibody to bind to H1-H16 and is protective in mice and ferrets. Multiple studies have shown that Fc-dependent mechanisms are essential for FI6 in vivo efficacy...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29723247/fc-engineering-of-anti-nectin-2-antibody-improved-thrombocytopenic-adverse-event-in-monkey
#4
Tsutomu Oshima, Hideaki Miyashita, Yoshimasa Ishimura, Yuki Ito, Yoko Tanaka, Akira Hori, Toshio Kokubo, Tomofumi Kurokawa
Nectin-2 is a transmembrane glycoprotein which is involved in the process of Ca2+-independent cell-cell adhesion. In our previous study, we have demonstrated that Nectin-2 is over-expressed in breast and ovarian cancer tissues by using gene expression analysis and immunohistochemistry. Furthermore, we discovered multiple anti-Nectin-2 fully human monoclonal antibodies which inhibited tumor growth in in vivo subcutaneous xenograft models with antibody-dependent cellular cytotoxicity (ADCC) as the principal mechanism of action...
2018: PloS One
https://www.readbyqxmd.com/read/29700387/multivalent-exposure-of-trastuzumab-on-iron-oxide-nanoparticles-improves-antitumor-potential-and-reduces-resistance-in-her2-positive-breast-cancer-cells
#5
Marta Truffi, Miriam Colombo, Luca Sorrentino, Laura Pandolfi, Serena Mazzucchelli, Francesco Pappalardo, Chiara Pacini, Raffaele Allevi, Arianna Bonizzi, Fabio Corsi, Davide Prosperi
Targeted therapies have profoundly changed the clinical prospect in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In particular, the anti-HER2 monoclonal antibody trastuzumab represents the gold standard for the treatment of HER2+ breast cancer patients. Its contribution in dampening cancer progression is mainly attributed to the antibody-dependent cell-mediated cytotoxicity (ADCC) rather than HER2 blockade. Here, multiple half chains of trastuzumab were conjugated onto magnetic iron oxide nanoparticles (MNP-HC) to develop target-specific and biologically active nanosystems to enhance anti-HER2 therapeutic potential...
April 26, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29686064/protection-from-cytomegalovirus-viremia-following-glycoprotein-b-vaccination-is-not-dependent-on-neutralizing-antibodies
#6
Ilona Baraniak, Barbara Kropff, Lyn Ambrose, Megan McIntosh, Gary R McLean, Sylvie Pichon, Claire Atkinson, Richard S B Milne, Michael Mach, Paul D Griffiths, Matthew B Reeves
Human cytomegalovirus (HCMV) is an important pathogen in transplant patients and in congenital infection. Previously, we demonstrated that vaccination with a recombinant viral glycoprotein B (gB)/MF59 adjuvant formulation before solid organ transplant reduced viral load parameters post transplant. Reduced posttransplant viremia was directly correlated with antibody titers against gB consistent with a humoral response against gB being important. Here we show that sera from the vaccinated seronegative patients displayed little evidence of a neutralizing antibody response against cell-free HCMV in vitro...
April 23, 2018: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29651286/iga-targeting-human-immunodeficiency-virus-1-envelope-gp41-triggers-antibody-dependent-cellular-cytotoxicity-cross-clade-and-cooperates-with-gp41-specific-igg-to-increase-cell-lysis
#7
Maxence Duchemin, Marwa Khamassi, Lin Xu, Daniela Tudor, Morgane Bomsel
The protective efficacy of human immunodeficiency virus-1 (HIV-1) antibodies (Abs) remains mostly correlated with their in vitro neutralizing activity engaging their Fab region. However, anti-HIV-1 Abs also mediate a broad array of Fc-mediated effector functions including Ab-dependent cellular cytotoxicity (ADCC), which depend primarily on the Ab isotype. While ADCC is commonly associated with HIV-1 gp120 envelope-specific IgGs, whether IgAs, especially those targeting the HIV-1 gp41 envelope, also mediate ADCC remains elusive...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29644082/characterisation-of-anifrolumab-a-fully-human-anti-interferon-receptor-antagonist-antibody-for-the-treatment-of-systemic-lupus-erythematosus
#8
Jeffrey M Riggs, Richard N Hanna, Bhargavi Rajan, Kamelia Zerrouki, Jodi L Karnell, Divya Sagar, Inna Vainshtein, Erika Farmer, Kimberly Rosenthal, Chris Morehouse, Melissa de Los Reyes, Kevin Schifferli, Meina Liang, Miguel A Sanjuan, Gary P Sims, Roland Kolbeck
Objective: We investigated the mechanistic and pharmacological properties of anifrolumab, a fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal antibody in development for SLE. Methods: IFNAR1 surface expression and internalisation on human monocytes before and after exposure to anifrolumab were assessed using confocal microscopy and flow cytometry. The effects of anifrolumab on type I IFN pathway activation were assessed using signal transducer and activator of transcription 1 (STAT1) phosphorylation, IFN-stimulated response element-luciferase reporter cell assays and type I IFN gene signature induction...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/29605231/neutrophils-mediate-hiv-specific-antibody-dependent-phagocytosis-and-adcc
#9
Matthew J Worley, Kuangyu Fei, Adam J Lopez-Denman, Anthony D Kelleher, Stephen J Kent, Amy W Chung
There is growing evidence to support the role of Fc-mediated effector functions, such as Antibody-Dependent Cellular cytotoxicity (ADCC) and Antibody-Dependent Phagocytosis (ADP) in the protection and control of HIV. The RV144 trial and other recent HIV vaccine studies have highlighted the importance of ADCC responses in protection against HIV. The role of neutrophils, the most abundant leukocyte in the blood, has not been thoroughly evaluated for Fc-mediated effector functions to HIV. We optimized HIV-specific neutrophil ADCC and Antibody-Dependent Neutrophil Phagocytosis (ADNP) assays using freshly isolated primary human neutrophils from blood...
March 29, 2018: Journal of Immunological Methods
https://www.readbyqxmd.com/read/29568351/targeting-of-embryonic-annexin-a2-expressed-on-ovarian-and-breast-cancer-by-the-novel-monoclonal-antibody-2448
#10
Simeon Cua, Heng Liang Tan, Wey Jia Fong, Angela Chin, Ally Lau, Vanessa Ding, Zhiwei Song, Yuansheng Yang, Andre Choo
Monoclonal antibodies (mAbs) play an increasingly important role in cancer therapy. To address the wide heterogeneity of the disease, the identification of novel antigen targets and the development of mAbs against them are needed. Our lab previously generated a panel of mAbs against human embryonic stem cells (hESC) using a whole cell immunization approach in mice. These mAbs can potentially target oncofetal antigens and be repurposed for antibody or antibody drug conjugate (ADC) therapy. From this panel, the novel IgG1 2448 was found to bind surface antigens on hESC and multiple cancer cell lines...
March 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29552307/characterization-of-7a7-an-anti-mouse-egfr-monoclonal-antibody-proposed-to-be-the-mouse-equivalent-of-cetuximab
#11
Xuzhi He, Jazmina L Cruz, Shannon Joseph, Nicola Pett, Hui Yi Chew, Zewen K Tuong, Satomi Okano, Gabrielle Kelly, Margaret Veitch, Fiona Simpson, James W Wells
The Epidermal Growth Factor Receptor (EGFR) is selectively expressed on the surface of numerous tumours, such as non-small cell lung, ovarian, colorectal and head and neck carcinomas. EGFR has therefore become a target for cancer therapy. Cetuximab is a chimeric human/mouse monoclonal antibody (mAb) that binds to EGFR, where it both inhibits signaling and induces cell death by antibody-dependent cell mediated cytotoxicity (ADCC). Cetuximab has been approved for clinical use in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal cancer...
February 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29548607/impact-of-pre-existing-immunity-on-the-induction-of-functional-cross-reactive-anti-hemagglutinin-stalk-antibodies-following-vaccination-with-an-as03-adjuvanted-pandemic-h1n1-vaccine
#12
Sarah M Tete, Åsne Jul-Larsen, Sina Rostami, Turid Helen Felli Lunde, Hanne Søland, Florian Krammer, Rebecca J Cox
The 2009 pandemic H1N1 (A(H1N1)pdm09) virus had a highly divergent hemagglutinin (HA) compared to pre-2009 seasonal H1N1 strains. Most peoples were immunologically naïve to the A(H1N1)pdm09, although hospital workers were exposed early in the pandemic before pandemic vaccines became available. Here, we evaluated how pre-existing antibodies influence the induction of cross-functional HA stalk antibodies following A(H1N1)pdm09 vaccination. Fifty-six healthcare workers vaccinated with AS03 adjuvanted A(H1N1)pdm09 vaccine were chosen by their pre-vaccination priming status (primed HI titers ≥ 40 or unprimed < 40)...
March 13, 2018: Vaccine
https://www.readbyqxmd.com/read/29541868/selection-of-a-ligand-binding-neutralizing-antibody-assay-for-benralizumab-comparison-with-an-antibody-dependent-cell-mediated-cytotoxicity-adcc-cell-based-assay
#13
Yuling Wu, Ahmad Akhgar, Jia J Li, Binbing Yu, Cecil Chen, Nancy Lee, Wendy I White, Lorin K Roskos
Assessment of anti-drug antibodies (ADAs) for neutralizing activity is important for the clinical development of biopharmaceuticals. Two types of neutralizing antibody (NAb) assays (competitive ligand-binding assay [CLBA] and cell-based assay [CBA]) are commonly used to characterize neutralizing activities. To support the clinical development of benralizumab, a humanized, anti-interleukin-5 receptor α, anti-eosinophil monoclonal antibody, we developed and validated a CLBA and a CBA. The CLBA and CBA were compared for sensitivity, drug tolerance, and precision to detect NAbs in serum samples from clinical trials...
March 14, 2018: AAPS Journal
https://www.readbyqxmd.com/read/29536036/human-cytomegalovirus-infection-increases-both-antibody-and-non-antibody-dependent-cellular-reactivity-by-natural-killer-cells
#14
Clive M Michelo, Bram van Cranenbroek, Peran Touw, Frans H J Claas, Arnold van der Meer, Irma Joosten
Background: Antibody-mediated rejection in solid organ transplantation is an important immunological barrier to successful long-term graft survival. Next to complement activation, natural killer (NK) cells have been implicated in the process. Human cytomegalovirus (CMV), independently associated with decreased graft survival, has a strong imprint on the immune response. Here, we assessed the effect of CMV status on alloreactive NK cell reactivity. Methods: We compared antibody-mediated NK cell cytolytic activity (CD107a expression) and IFNγ production between healthy CMV-seropositive (n = 8) and CMV-seronegative (n = 11) individuals, in cocultures of NK cells with anti-HLA class I or rituximab (control) antibody-coated Raji cells...
December 2017: Transplantation Direct
https://www.readbyqxmd.com/read/29523166/predominant-envelope-variable-loop-2-specific-and-gp120-specific-antibody-dependent-cellular-cytotoxicity-antibody-responses-in-acutely-siv-infected-african-green-monkeys
#15
Quang N Nguyen, David R Martinez, Jonathon E Himes, R Whitney Edwards, Qifeng Han, Amit Kumar, Riley Mangan, Nathan I Nicely, Guanhua Xie, Nathan Vandergrift, Xiaoying Shen, Justin Pollara, Sallie R Permar
BACKGROUND: The initial envelope (Env)-specific antibody response in acutely HIV-1-infected individuals and simian immunodeficiency virus (SIV)-infected rhesus monkeys (RMs) is dominated by non-neutralizing antibodies targeting Env gp41. In contrast, natural primate SIV hosts, such as African green monkeys (AGMs), develop a predominant Env gp120-specific antibody response to SIV infection. However, the fine-epitope specificity and function of SIV Env-specific plasma IgG, and their potential role on autologous virus co-evolution in SIV-infected AGMs and RMs remain unclear...
March 9, 2018: Retrovirology
https://www.readbyqxmd.com/read/29498807/application-of-area-scaling-analysis-to-identify-natural-killer-cell-and-monocyte-involvement-in-the-grantoxilux-antibody-dependent-cell-mediated-cytotoxicity-assay
#16
Justin Pollara, Chiara Orlandi, Charles Beck, R Whitney Edwards, Yi Hu, Shuying Liu, Shixia Wang, Richard A Koup, Thomas N Denny, Shan Lu, Georgia D Tomaras, Anthony DeVico, George K Lewis, Guido Ferrari
Several different assay methodologies have been described for the evaluation of HIV or SIV-specific antibody-dependent cell-mediated cytotoxicity (ADCC). Commonly used assays measure ADCC by evaluating effector cell functions, or by detecting elimination of target cells. Signaling through Fc receptors, cellular activation, cytotoxic granule exocytosis, or accumulation of cytolytic and immune signaling factors have been used to evaluate ADCC at the level of the effector cells. Alternatively, assays that measure killing or loss of target cells provide a direct assessment of the specific killing activity of antibodies capable of ADCC...
April 2018: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
https://www.readbyqxmd.com/read/29491709/investigation-of-antitumor-activities-of-trastuzumab-delivered-by-plga-nanoparticles
#17
Barbara Colzani, Laura Pandolfi, Ada Hoti, Pietro Alessandro Iovene, Antonino Natalello, Svetlana Avvakumova, Miriam Colombo, Davide Prosperi
Background: We report the development of an efficient antibody delivery system for the incorporation of trastuzumab (TZ) into poly(lactic- co -glycolic) acid nanoparticles (PLGA NPs). The aim of the work was to overcome the current limitations in the clinical use of therapeutic antibodies, including immunogenicity, poor pharmacokinetics, low tumor penetration and safety issues. Materials and methods: Trastuzumab-loaded PLGA NPs (PLGA-TZ) were synthesized according to a double emulsion method...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29490608/the-effects-of-trastuzumab-on-her2-mediated-cell-signaling-in-cho-cells-expressing-human-her2
#18
Hamid Maadi, Babak Nami, Junfeng Tong, Gina Li, Zhixiang Wang
BACKGROUND: Targeted therapy with trastuzumab has become a mainstay for HER2-positive breast cancer without a clear understanding of the mechanism of its action. While many mechanisms have been suggested for the action of trastuzumab, most of them are not substantiated by experimental data. It has been suggested that trastuzumab functions by inhibiting intracellular signaling initiated by HER2, however, the data are very controversial. A major issue is the different cellular background of various breast cancer cells lines used in these studies...
March 1, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29478343/pd-l1-inhibition-with-avelumab-for-metastatic-merkel-cell-carcinoma
#19
REVIEW
Maria Rita Gaiser, Michelle Bongiorno, Isaac Brownell
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer that lacks durable responses to traditional chemotherapy. Areas covered: After MCC was shown to be an immunogenic tumor, small trials revealed high objective response rates to PD-1/PD-L1 checkpoint inhibitors. The JAVELIN Merkel 200 (NCT02155647) trial tested the use of avelumab, a human IgG1 monoclonal antibody against PD-L1, in metastatic MCC. Avelumab recently became the first approved drug for metastatic MCC. Expert commentary: By conducting broad phase I studies assessing the safety of avelumab and a small phase II study demonstrating efficacy in this rare orphan tumor type, avelumab gained accelerated approval for the treatment of metastatic MCC...
April 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29438058/assessment-of-antibody-dependent-cellular-cytotoxicity-by-flow-cytometry
#20
Thomas D Duensing, Susan R Watson
A useful feature of therapeutic antibodies is the ability to kill the cells to which they bind. Antibodies are capable of mediating cell killing in a variety of ways. Apoptosis, complement-mediated mechanisms, and antibody-dependent cellular cytotoxicity (ADCC) are all effects that can be assayed to characterize lead antibody candidates. Extensive, multidose characterizations of a series of candidates can be performed in a short amount of time using assays developed for high-throughput flow cytometry systems...
February 1, 2018: Cold Spring Harbor Protocols
keyword
keyword
72920
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"